Literature DB >> 28968158

SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.

Kyra B Berg, David F Schaeffer.   

Abstract

SATB2 is part of the family of matrix attachment region-binding transcription factors, and has developmental roles in craniofacial, neural, and osteoblastic differentiation. Recently, SATB2 has been shown to be highly expressed in the epithelium of the lower gastrointestinal tract, with a relatively narrow expression profile in malignancies, including colorectal/appendiceal adenocarcinomas, tumors of osteoblastic differentiation, and renal/urothelial carcinomas. SATB2 has gained interest as a relatively specific marker of colorectal differentiation, with potential applications including determining origin of adenocarcinomas of unknown primary and distinguishing primary ovarian mucinous adenocarcinomas from colorectal metastases. Here, we briefly review the biology, expression profile, and potential histologic applications of SATB2.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28968158     DOI: 10.5858/arpa.2016-0243-RS

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  12 in total

1.  SATB2 targeted by methylated miR-34c-5p suppresses proliferation and metastasis attenuating the epithelial-mesenchymal transition in colorectal cancer.

Authors:  Jingfeng Gu; Guiqi Wang; Haixia Liu; Chaohui Xiong
Journal:  Cell Prolif       Date:  2018-04-27       Impact factor: 6.831

2.  Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.

Authors:  Ji Ae Lee; Mi-Kyoung Seo; Seung-Yeon Yoo; Nam-Yun Cho; Yoonjin Kwak; Kyoungbun Lee; Jung Ho Kim; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.064

3.  SATB2 Shows Different Profiles Between Appendiceal Adenocarcinomas Ex Goblet Cell Carcinoids and Appendiceal/Colorectal Conventional Adenocarcinomas: An Immunohistochemical Study With Comparison to CDX2.

Authors:  Chen Yang; Li Sun; Lingxin Zhang; Lixin Zhou; Dongfeng Niu; Wenfeng Cao; Zhongwu Li; Xiaozheng Huang; Qiang Kang; Lin Jia; Marina Platik; Xiuli Liu; Jinping Lai; Dengfeng Cao
Journal:  Gastroenterology Res       Date:  2018-05-31

Review 4.  Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics.

Authors:  Pavel Dundr; Naveena Singh; Barbora Nožičková; Kristýna Němejcová; Michaela Bártů; Ivana Stružinská
Journal:  Diagn Pathol       Date:  2021-03-11       Impact factor: 2.644

5.  SLC25A21 Suppresses Cell Growth in Bladder Cancer via an Oxidative Stress-Mediated Mechanism.

Authors:  Yong Wang; Jiawen Gao; Shasha Hu; Weiting Zeng; Hongjun Yang; Hui Chen; Shuang Wang
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

6.  Pancreatic cancer with synchronous liver and colon metastases: A case report.

Authors:  Yuan-Mei Dong; Hong-Nian Sun; De-Cong Sun; Mu-Hong Deng; Yong-Gang Peng; Yan-Yun Zhu
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

7.  Secondary Involvement of the Uterine Cervix by Nongynecologic Neoplasms: A Detailed Clinicopathologic Analysis.

Authors:  Gulisa Turashvili; Wesley R Samore; Esther Oliva; Olga Ioffe; Robert Riddell; Kay J Park; Lars-Christian Horn
Journal:  Am J Surg Pathol       Date:  2020-12       Impact factor: 6.298

8.  Newly established gastrointestinal cancer cell lines retain the genomic and immunophenotypic landscape of their parental cancers.

Authors:  Daniela Hirsch; Steffen Seyfried; Tobias Staib; David Fiedler; Christian Sauer; Thomas Ried; Stephanie Witt; Felix Rueckert; Timo Gaiser
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

Review 9.  Novel Diagnostic Biomarkers in Colorectal Cancer.

Authors:  Aneta L Zygulska; Piotr Pierzchalski
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

10.  Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups.

Authors:  Maxime Schmitt; Miguel Silva; Björn Konukiewitz; Corinna Lang; Katja Steiger; Kathrin Halfter; Jutta Engel; Paul Jank; Nicole Pfarr; Dirk Wilhelm; Sebastian Foersch; Carsten Denkert; Markus Tschurtschenthaler; Wilko Weichert; Moritz Jesinghaus
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.